Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFLECTIONS B327-02: Trazimera vs Trastuzumab in Metastatic Breast Cancer
NCT01989676Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2014
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab-qyyp in HER2-positive metastatic breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Objective Response Rate at Week 33. Started Feb 2014; status: completed.
02
Drugs
trastuzumab-qyyp
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01989676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989676.